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a b s t r a c t
After introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the infant national immu-
nization program (NIP) in the Netherlands in 2006, Streptococcus pneumoniae strains of the non-vaccine
serotype 19A emerged and became the dominant serotype in carriage in children and their parents. Sim-
ilar patterns were observed in other European countries and the United States. Increases in carriage rates
of Staphylococcus aureus and non-typeable (NT)Haemophilus inﬂuenzaewere also observed. After switch-
ing of PCV7 to 10-valent vaccine (PCV10) in 2011, a new carriage surveillance studywas performed in the
winter of 2012/2013. Nasopharyngeal carriage of S. pneumoniae, H. inﬂuenzae, S. aureus, and Moraxella
catarrhalis was determined by conventional culture in 330 PCV10-vaccinated 11-month-old children,
330 PCV7-vaccinated 24-month-old children, and their parents. Carriage prevalence was compared with
similar carriage studies conducted in 2005, 2009, and 2010/2011. Although serotype 19A remained the
most frequently carried pneumococcal serotype in children, prevalence of 19A signiﬁcantly declined in
PCV7-vaccinated 24-month-old children (14% to 8%, p=0.01), but less in PCV10-vaccinated 11-month-
old children (12% to 9%, p=0.31). Carriage of H. inﬂuenzae remained stable at an elevated level (65% in
11-month-olds and 69% in 24-month-olds), while the carriage of S. aureus returned to pre-PCV7 levels in
11-month-old children (14% in 2010/2011 to 7% in 2012/2013), but not in 24-month-olds (remained at
7%). Our results might indicate a new balance between replacing non-vaccine pneumococcal serotypes
and other potential pathogenic bacteria in nasopharyngeal carriage. Carriage studies are valuable tools
in assessing vaccine effects on pathogens circulating in the population, for evaluation of PCV impact, and
in predicting changes in respiratory and invasive disease.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND. Introduction
Streptococcus pneumoniae (pneumococcus) is a leading cause
f respiratory infections like pneumonia and acute otitis media,
s well of invasive disease including septicaemia and meningitis.
neumococcal disease is preceded by nasopharyngeal acquisition.
urveillances on asymptomatic colonization and carriage preva-
ence are therefore important tools in monitoring effects and
redicting impact of vaccines targeting disease [1–4].
∗ Corresponding author.
E-mail address: L.Sanders@umcutrecht.nl (E.A.M. Sanders).
ttp://dx.doi.org/10.1016/j.vaccine.2015.11.060
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The upper respiratory tract in children is an important reser-
voir for commonrespiratorybacterial pathogens likeS. pneumoniae,
Staphylococcus aureus, (non-typeable) Haemophilus inﬂuenzae, and
Moraxella catarrhalis, which usually behave like commensals but
occasionally cause respiratory or invasive infectious disease [5]. In
particular young children with high colonization prevalence and
high carriage density are considered to be a major source for trans-
mission and spread of respiratory pathogens in the community
[6,7]. There are clear differences in carriageprevalence [8] and inva-
siveness [9,10] between the more than 90 different pneumococcal
serotypes that are currently identiﬁed. Around 20 serotypes caused
70–80% of all invasive pneumococcal disease (IPD) in children
before the introduction of pneumococcal conjugate vaccines(PCV)
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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11]. Reduction of pneumococcal vaccine serotype carriage through
CV vaccination of children has led to important herd protection
gainst disease caused by vaccine type pneumococci in all age
roups [12–15].
In the Netherlands, PCV7 was introduced in the national immu-
ization program (NIP) in June 2006 for all newborns at the age
f 2, 3, 4, and 11 months without a catch-up for older infants and
oddlers. In 2011, the 10-valent pneumococcal conjugate vaccine
PCV10) replaced PCV7 for all children born after March 1st with-
ut catch-up. PCV10 includes serotypes 1, 5 and 7F next to the PCV7
accine serotypes; eight of the ten PCV10 serotypes are conjugated
o Protein D, a conserved outer membrane protein of non-typeable
. inﬂuenzae, whereas the two remaining are conjugated to either
etanus toxoid or diphtheria toxoid as carrier protein.
In our previous carriage monitoring studies in infants, we found
n initial decline of 20% in overall pneumococcal carriage preva-
ence due to a strong drop of vaccine serotype carriage [12]. Over
ime, the vacant nasopharyngeal niche was gradually ﬁlled in by
on-vaccine serotypes in PCV7-vaccinated toddlers as shown in
ur carriage surveillance studies from 2009 [16] and 2010/2011
17], and by others [18,19]. In particular, carriage of serotype
9A showed high carriage peaks in infants with carriage preva-
ence up to 14% in 2010/2011 and became the primary colonizing
erotype in children in the Netherlands [16,17]. Dominance of
erotype 19A in both carriage and disease after the implementa-
ion of PCV7was also observed in other European countries and the
SA [19,20,21,22,23,24]. Next to a shift in pneumococcal serotypes,
ncreased carriage prevalence of H. inﬂuenzae and S. aureus were
bserved after PCV7 implementation [16,17]. This raises concerns
bout the potential impact of PCV7 on non-pneumococcal infec-
ions.
Epidemiological surveillance of pneumococcal carriage is an
ffective tool to monitor PCV-induced changes and to predict vac-
ine effects on pneumococcal disease [3,4]. As part of our on-going
neumococcal surveillance program, we evaluated the long-term
mpact of PCVs on both pneumococcal carriage and carriage of
ther respiratory bacterial pathogens. We performed the current
tudy seven years after PCV7 introduction in the Dutch national
mmunization program and 1.5 years after PCV7 was replaced by
CV10.
. Methods
.1. Study population
Nasopharyngeal carriage of S. pneumoniae, S. aureus, H. inﬂuen-
ae, and M. catarrhalis was investigated from October 1st, 2012
hrough March 5th, 2013 in two age cohorts from the open popu-
ation of children: (1) 330 11-month-old infants who had received
CV10 at 2, 3, and 4 months of age according to the Dutch national
mmunization program (NIP) (born after March 1st 2011), and
efore the booster vaccination at 11 months of age, (2) 330 24-
onth-old children who were immunized with PCV7 at 2, 3, 4, and
1 months of age (born before March 1st 2011). (3) Additionally,
asopharyngeal and oropharyngeal samples were collected from
neof theparents of each24-month-old child. All participantswere
on-febrile (i.e. <38.5 ◦C body temperature) at sampling. Exclusion
riteria were known or suspected immunodeﬁciency, craniofacial
r chromosomal abnormalities, coagulation disorders, or use of
nticoagulantmedication. Participants did not receive anyﬁnancial
ompensation. An acknowledged national ethics committee in the
etherlands (METC Noord-Holland, committee on research involv-
ng human subjects) approved the study (NL40288.094.12). The
tudy was conducted in accordance with the European Statements
or Good Clinical Practice.e 34 (2016) 531–539
Current data was compared with historical data from PCV-
unvaccinated children at 12 and 24months of age and one parent of
each 24-month-old child, derived fromaprevious longitudinal ran-
domized controlled trial (RCT) in the Netherlands (NCT00189020)
which was executed between 2005 and 2008 [12]. In addition, cur-
rent data from 2012/2013 were compared with previous carriage
data from similarly designed cross-sectional carriage surveillance
studies executed in 2009 and 2010/11, i.e. 3 years [16] and 4.5 years
after implementation of PCV7 in the NIP in 2006 [17], the latter
immediately prior to introduction of PCV10 for children born after
March 1, 2011. All studies were conducted in an open population
living in the Western part of the Netherlands and performed by the
same study team.
2.2. Nasopharyngeal swabs
Nasopharyngeal swabs were obtained transnasally by trained
study personnel with a ﬂexible, sterile swab according to World
Health Organization standard procedures as previously described
[25]. From parents, both transnasal and transoral nasopharyngeal
samples were collected, as the pneumococcal yield is known to
be higher in adults when taking both samples [26]. After samp-
ling, swabs were immediately placed in liquid Amies transport
medium and cultured within 12h. All swabs in present and previ-
ous studies were processed by the same microbiological laboratory
and according to the same study procedures, as described ear-
lier [12,27]. Brieﬂy, pneumococcal isolates were identiﬁed using
conventional methods; one pneumococcal colony per plate was
subcultured and serotyped by capsular swelling method (Quel-
lung reaction). For S. aureus, H. inﬂuenzae, and M. catarrhalis,
swabs were cultured according to standard diagnostic proce-
dures.
2.3. Questionnaire
Research nurses completed a survey of each child and parent on
possible predictors of nasopharyngeal bacterial carriage: age, sex,
season of sampling, recent antibiotic use within one month prior
to sampling, symptoms of a respiratory tract infection and/or acute
otitis media during sampling, presence of siblings in the house-
hold, day care attendance of the participating child, passive smoke
exposure indoors, and active smoking of the participating parent.
2.4. Statistical analyses
The sample size of the present surveillance study was similar
to the previous cross-sectional studies [16,17], on the assump-
tion that in all studies at least similar but presumably signiﬁcantly
larger differences would be observed in carriage of vaccine
serotypes compared to the unvaccinated historical cohort from
2005.
Differences in baseline characteristics were statistically tested
using2-sidedChi-square or Fisher’s exact test for dichotomousout-
comes and Student’s t-test for continuous outcomes. Differences in
prevalence of pneumococcal serotypes andother respiratory bacte-
ria were statistically tested using 2-sided Chi-square or Fisher’s
exact test, where appropriate. p-Values <0.05 were considered sig-
niﬁcant. A backward stepwise logistic regression (with backward
variable selection based on likelihood ratio test) was used to deter-
mine adjusted estimates of the association between the bacterial
carriage and pneumococcal vaccination, as given by adjusted odds
ratios (aORs) and their corresponding 95% conﬁdence intervals
(CIs). Entered possible predictors included above-mentioned pos-
sible predictors of nasopharyngeal carriage. Due to the low amount
of missing data (<0.1%) no imputation methods were used.
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Table 1
Baseline characteristics of all four studies.
11 Months children 24 Months children
2005
Pre-PCV7
2009
Post-PCV7
3yr
2010/2011
Post-PCV7
4.5 yr
2012/2013
Post-PCV10
1.5 yr
2005
Pre-PCV7
2009
Post-PCV7
3yr
2010/2011
Post-PCV7
4.5 yr
2012/2013
Post-PCV7
6.5 yr
No (%)
n=319
No (%)
n=329*
No (%)
n=330
No (%)
n=330
No (%)
n=321
No (%)
n=330
No (%)
n=330
No (%)
n=330
Male sex 156 (49) 181 (55) 173 (52) 176 (53) 155 (48) 187 (57)a 171 (52) 145 (44)e
Mean age in months (SD) 12.0 (0.3) 10.9 (0.3)a 10.7 (0.4)b,c 10.8 (0.3)d,e,f 24.2 (0.6) 24.0 (0.3)a 23.8 (0.5)b,c 24.2 (0.4)e,f
Presence of siblings <5yr§ 126 (40) 84 (26)a 145 (44)c 152 (46)e 127 (40) 135 (41) 154 (47) 130 (39)
Day care attendance§ 208 (65) 226 (69) 222 (67) 237 (72) 224 (70) 233 (71) 259 (79)b 253 (77)
Passive smoke exposure¶ 21 (7) 5 (2)a 9 (3)b 8 (2) 26 (8) 16 (5) 12 (4)b 14 (4)
Symptoms of RTI and/or
AOM#
95 (30) 95 (29) 112 (34) 93 (28) 82 (26) 69 (21) 114 (35)b,c 89 (27)f
Antimicrobial drug use** 20 (6) 24 (7) 27 (8)b 35 (11) 10 (3) 23 (7)a 15 (5)b 21 (6)
Period of sampling:
October–March 149 (47) 82 (25)a 274 (83)b,c 330 (100) 156 (48) 86 (26)a 299 (91)b,c 330 (100)
April–September 170 (53) 247 (75) 56 (17)¥ – 166 (52) 244 (74) 31 (9)¥ –
Parents of 24-month-old children (unvaccinated)
2005
Pre-PCV7
2009
Post-PCV7
3yr
2010/2011
Post-PCV7
4.5yr
2012/2013
Post-PCV7
6.5yr
n (%) n (%) n (%) n (%) (a) p-values <0.05; 2009 vs. 2005
n=296 n=324 n=326 n=322 (b) p-values <0.05; 2010/2011 vs. 2005
Male sex 51 (17) 53 (16) 58 (18) 61 (19) (c) p-values <0.05; 2010/2011 vs. 2009
Mean age in years (SD) 34.7 (4.9) 35.1 (4.4) 35.3 (4.5) 35.8 (4.6) (d) p-values <0.05; 2012/2013 vs. 2005
Active smoking 40 (14) 34 (11) 41 (13) 45 (14) (e) p-values <0.05; 2012/2013 vs.2009
Antimicrobial drug use** 9 (3) 20 (6) 16 (5) 15 (5) (f) p-values <0.05; 2012/2013 vs.2010/2011
Abbreviations: PCV7; all serotypes included in 7-valent pneumococcal conjugate vaccine. PCV10; all serotypes included in 10-valent pneumococcal conjugate vaccine. SD;
standard deviation; p-values were calculated with chi-square test or Fisher’s exact test (2-sided) or independent-samples t-test where appropriate.
* Swabs were taken just before the booster vaccination at 11 months of age or within one week after the booster vaccination.
§ Deﬁned as more than 4h per week with at least 1 child from a different household.
¶ Deﬁned as passive tobacco smoke exposure indoors at least 1 cigar or cigarette during 5 days/week.
# The presence of symptoms of a respiratory tract infection (RTI) and/or acute otitis media (AOM) as deﬁned by evaluation of parents.
** Deﬁned as use of oral or intravenous antibiotics within 1 month before sampling.
¥ Samples were collected between 15th and 30th of September.
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In total, 330 children aged 11 months, 330 children aged 24
onths, and 322 parents were sampled. Baseline characteristics
f children and parents of the current study (2012/2013) and the
revious studies are shown in Table 1. The most noticeable differ-
nce among these four time-points is the season of sampling. The
urrent study and the follow-up study in 2010/2011were both per-
ormed during the autumn/winter whereas samples in the studies
f 2005 and2009were also collectedduring the spring and summer
onths.Weobservednosigniﬁcant effect of seasononpneumococ-
al carriage prevalence by conventional culture, except for carriage
f M. catarrhalis, which seemed to be higher during the summer
onths (data not shown). We corrected for this in the multivariate
nalyses.
In 2012/2013, pneumococcal carriage prevalence in children
as lower than the pre-vaccination level of 2005 (respectively
9% vs. 67% in 11-months-olds (p=0.03) and 56% vs. 66% in
4-months-olds (p=0.01)). In parents, the overall pneumococcal
arriage prevalence was lower as compared to all previous years
Fig. 1A and Table 2).
Both in childrenandparents,weobservedanearly completedis-
ppearance of PCV7-serotypes (carriage <2%) as compared to 2005.
he carriage of the additional PCV10 serotypes (serotypes 1, 5 and
F) was below 2% in children in all four consecutive studies (Fig. 1A
nd B, and Supplemental Table 1).Non-PCV7 serotype carriage prevalence had almost doubled
ver time after introduction of PCV7; from 29% in 2005 to 57%
n 2012/2013 in 11-month-old children and from 30% to 55% in24-month-old children. In parents, all except one (serotype 6B) of
31 cultured pneumococci were non-PCV7 serotypes in 2012/2013
(Fig. 1A and B and Supplemental Table 1).
Carriage of serotype 19A increased over the years after
PCV7 introduction. In 2012/2013, 19A remained the predominant
serotype in carriage in children, although the prevalence of 19A
had signiﬁcantly declined since 2010/2011 in the 24-month-olds
(14% to 8%, p=0.01), whereas serotype 19A carriage prevalence had
remained stable at around 10% in PCV10-vaccinated 11-month-old
children (Fig. 1B and Supplemental Table 1). In infants, 19Awas fol-
lowed by the serotypes 6C, 23B, 23A, and 11A. In parents, serotype
10A was the most predominant serotype, followed by 23B, 19A,
and 3 (Fig. 1B and Supplemental Table 1). After implementation of
PCV7, carriageof 6Adeclined rapidly and remained low (around1%)
in 2012/2013 in children and parents. Carriage of serotype 3, also
covered by the 13-valent vaccine but not in PCV10, remained low
in all study groups. Serotype 6C had increased after PCV implemen-
tation in both PCV10-vaccinated 11-month-olds (from 2% in 2005
to 6% in 2012/2013) and PCV7-vaccinated 24-month-olds (from 2%
in 2005 to 7% in 2012/2013).
For S. aureus, after a stepwise progressive rise in 2009 and
2010/2011 to up to 14% in 11-month-old children, the prevalence
had returned to pre-PCV7 levels of around 7% in 2012/2013. In
parents, S. aureus carriage remained at a higher level of 32% as
compared to 20% in 2005. In 24-month-old children, no changes
in S. aureus carriage were observed between 2005 and 2012/2013
(Table 2 and Fig. 2A).
Carriage prevalence of H. inﬂuenzae had increased in the years
after PCV7 implementation in all age groups and remained at a
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Fig. 1. Carriage of S. pneumoniae in children and parents depicted over time. The ﬁrst bar in each age group depicts the carriage prevalence before the implementation of PCV
(2005). The following three bars depict the carriage prevalence as observed during the follow-up studies; respectively 3 years after PCV implementation (2009), 4.5 years
after PCV implementation (2010/2011) and in the 7th year after PCV implementation (2012/2013).
(A) Overall pneumococcal carriage, ## adjusted Odds Ratio does not include 1, compared with linked bar on overall pneumococcal carriage. * Adjusted Odds Ratio does not
include 1, compared to pre-PCV7 data on carriage of PCV7 serotypes and carriage of non-PCV7 serotypes (panel A). (B) Carriage of pneumococcal serotypes. Abbreviations:
PCV7; all serotypes included in 7-valent pneumococcal conjugate vaccine. PCV10; all serotypes included in 10-valent pneumococcal conjugate vaccine.
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Table 2
Multivariate analysis of nasopharyngeal carriage of S. pneumoniae, S. aureus, H. inﬂuenzae and M. catarrhalis before, 3, 4.5 and 6.5 years after PCV implementation among children and their parents.
2005
Pre-PCV7
2009
Post-PCV7
3yr
2010/2011
Post-PCV7
4.5 yr
2012/2013
Post-PCV10
1.5 year
2009 vs
2005
2010/2011 vs
2005
2012/2013 vs
2005
2010/2011 vs
2009
2012/2013 vs
2009
2012/2013 vs
2010/2011
No (%) No (%) No (%) No (%) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI)
11 months n=319 n=329 n=330 n=330
S. pneumoniae 214 (67) 154 (47) 173 (52) 193 (59) 0.43 (0.30–0.60) 0.48 (0.34–0.67) 0.63 (0.45–0.89) 1.02 (0.68–1.53) 1.49 (1.07–2.09) 1.34 (0.96–1.88)
PCV7-serotypes 122 (38) 25 (8) 10 (3) 7 (2) 0.14 (0.09–0.23) 0.04 (0.02–0.08) 0.03 (0.01–0.06) 0.38 (0.18–0.80) 0.26 (0.11–0.62) 0.83 (0.28–2.38)
Non-PCV7-serotypes 92 (29) 129 (39) 163 (50) 186 (57) 1.75 (1.24–2.46) 2.59 (1.85–3.62) 3.58 (2.54–5.05) 1.39 (1.00–1.93) 1.92 (1.37–2.69) 1.40 (1.00–1.96)
PCV10-serotypes 124 (39) 26 (8) 12 (4) 7 (2) 0.14 (0.09–0.23) 0.05 (0.03–0.09) 0.03 (0.01–0.06) 0.44 (0.55–0.89) 0.26 (0.11–0.60) 0.58 (0.23–1.50)
S. aureus 16 (5) 31 (9) 46 (14) 23 (7) 1.79 (0.95-3.38) 3.27 (1.78–5.98) 1.54 (0.79–3.00) 1.88 (1.14–3.13) 0.88 (0.49–1.57) 0.47 (0.28–0.80)
H. inﬂuenzae 146 (46) 212 (64) 213 (65) 209 (63) 2.69 (1.90–3.80) 2.22 (1.58–3.13) 1.96 (1.40–2.75) 0.83 (0.59–1.17) 0.73 (0.52–1.03) 0.89 (0.64–1.25)
M. catarrhalis 218 (68) 210 (64) 251 (76) 263 (80) 0.81 (0.57–1.15) 1.45 (1.00–2.10) 1.33 (0.87–2.04) 1.82 (1.27–2.61) 2.09 (1.43–3.04) 0.80 (0.53–1.19)
2005
Pre-PCV7
2009
Post-PCV7
3yr
2010/2011
Post-PCV7
4.5 yr
2012/2013
Post-PCV7
6.5 year
2009 vs 2005 2010/2011 vs
2005
2012/2013 vs
2005
2010/2011 vs
2009
2012/2013 vs
2009
2012/2013 vs
2010/2011
No (%) No (%) No (%) No (%) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI) aOR (95% CI)
24 months n=321 n=330 n=330 n=330
S. pneumoniae 211 (66) 162 (49) 211 (64) 185 (56) 0.50 (0.36–0.70) 0.81 (0.58–1.13) 0.62(0.44–0.86) 1.61 (1.16–2.23) 1.25 (0.91–1.72) 0.79 (0.57–1.10)
PCV7-serotypes 114 (36) 14 (4) 11 (3) 2 (1) 0.08 (0.05–0.15) 0.06 (0.03–0.12) 0.01 (0.00–0.04) 0.76 (0.34–1.70) 0.14 (0.03–0.61) 0.18 (0.04–0.80)
Non-PCV7-serotypes 97 (30) 148 (45) 200 (61) 183 (55) 1.99 (1.43–2.77) 3.35 (2.40–4.67) 3.14 (2.25–4.38) 1.67 (1.21–2.30) 1.46 (1.06–2.01) 0.89 (0.64–1.24)
PCV10-serotypes 118 (37) 15 (5) 16 (5) 7 (2) 0.08 (0.05–0.15) 0.09 (0.05–0.15) 0.04 (0.02–0.08) 1.00 (0.49–2.07) 0.45 (0.18–1.11) 0.43 (0.17–1.05)
S. aureus 18 (6) 25 (8) 24 (7) 22 (7) 1.39 (0.74–2.63) 1.61 (0.84–3.07) 1.29 (0.67–2.48) 1.09 (0.60–1.97) 0.94 (0.51–1.72) 0.81 (0.44–1.49)
H. inﬂuenzae 168 (52) 240 (73) 252 (76) 227 (69) 2.70 (1.91–3.82) 2.68 (1.88–3.82) 2.00 (1.42–2.82) 0.99 (0.68–1.44) 0.76 (0.53–1.09) 0.77 (0.53–1.11)
M. catarrhalis 189 (59) 199 (60) 264 (80) 251 (76) 1.37 (0.97–1.94) 1.75 (1.18–2.61) 1.29 (0.86–1.98) 1.37 (0.85–2.21) 0.96 (0.58–1.61) 1.01 (0.66–1.55)
2005 2009 2010/2011 2012/2013 2009 vs
2005
2010/2011 vs
2005
2012/2013 vs
2005
2010/2011 vs
2009
2012/2013 vs
2009
2012/2013 vs
2010/2011
No (%) No (%) No (%) No (%) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) aOR (95% CI) aOR (95% CI)
Parents n=296 n=324 n=326 n=322
S. pneumoniae 50 (17) 51 (16) 68 (21) 31 (10) 0.91 (0.59–1.40) 1.27 (0.84–1.91) 0.52 (0.32–0.84) 1.35 (0.90–2.02) 0.57 (0.35–0.92) 0.42 (0.27–0.66)
PCV7-serotypes 25 (8) 2 (1) 7 (2) 1 (0) 0.07 (0.02–0.29) 0.24 (0.10–0.55) 0.03 (0.01–0.25) 4.09 (0.83–20.1) 0.50 (0.04–5.54) 0.22 (0.03–2.00)
Non-PCV7-serotypes 25 (8) 49 (15) 61 (19) 30 (9) 1.93 (1.16–3.23) 2.43 (1.48–4.00) 0.95 (0.53–1.68) 1.25 (0.82–1.89) 0.48 (0.29–0.80) 0.38 (0.23–0.91)
S. aureus 60 (20) 104 (32) 111 (34) 104 (32) 1.85 (1.36–2.83) 1.96 (1.36–2.83) 1.86 (1.29–2.69) 1.07 (0.77–1.49) 0.79 (0.49–1.28) 0.82 (0.59–1.15)
H. inﬂuenzae 67 (23) 96 (30) 130 (40) 111 (35) 1.49 (1.03–2.14) 2.26 (1.58–3.33) 1.85 (1.29–2.64) 1.52 (1.10–2.11) 1.22 (0.88–1.71) 0.79 (0.58–1.09)
M. catarrhalis 28 (10) 43 (13) 71 (22) 61 (19) 1.44 (0.87–2.39) 2.54 (1.59–4.08) 2.22 (1.38–3.58) 1.77 (1.17–2.69) 1.29 (0.71–2.33) 0.80 (0.54–1.17)
Abbreviations: PCV7; all serotypes included in 7-valent pneumococcal conjugate vaccine. Non-PCV7; all other serotypes not included in 7-valent pneumococcal conjugate vaccine. PCV10; all serotypes included in 10-valent
pneumococcal conjugate vaccine. aOR; adjusted odds ratio. CI; conﬁdence interval. In children; aOR-values were adjusted by multivariate analysis for sex; presence of siblings <5yr in the household; day care attendance;
antibiotic use; passive smoke exposure; season; and the presence of URTI and/or AOM using binary logistic regression with backward LR. In parents; aOR-values were adjusted by multivariate analysis for sex; smoking;
antibiotics use; and season using binary logistic regression with backward LR. Bold indicates the signiﬁcant aORs.
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Fig. 2. Carriage of S. aureus, H. inﬂuenzae and M. catarrhalis in children and parents
depicted over time. (A) Carriage of S. aureus. (B) Carriage ofH. inﬂuenzae. (C) Carriage
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if M. catarrhalis, ## adjusted Odds Ratio does not include 1 compared with linked
ar on carriage of S. aureus (panel B), H. inﬂuenzae (panel C) and M. catarrhalis (panel
).
igher level of 63–69% in children and 35% in parents. Carriage
f M. catarrhalis remained stable over time after PCV introduction
Table 2 and, respectively Fig. 2B and C).
. Discussion
After introduction of PCV7 in the NIP in 2006, carriage of PCV7
erotypes had rapidly declined toward a very low level, both in
accinated children and their parents. Simultaneously, an almost
omplete replacement with non-vaccine pneumococcal strains
ccurred over the years, with strains of serotype 19A becom-
ng the predominant pneumococci in carriage and progressivelye 34 (2016) 531–539
increasing prevalence until 2010/2011. In 2012/2013, this serotype
19A expansion was no longer observed; 19A carriage had declined
signiﬁcantly in the 24-month-old children who had received four
PCV7 vaccinations, but not in 11-months-olds vaccinated with
threedoses of PCV10. IPD caseswith serotype19A in childrenunder
ﬁve years of age also declined since 2011 in the Netherlands [28].
Several studies have reported on potential cross-protection against
serotype 19A by PCV10 in IPD [29,30]. Our data does not sup-
port PCV10-induced cross-protection in carriage since the decline
in 19A prevalence was more outspoken in the PCV7-vaccinated
24-month-old children than in the PCV10-vaccinated 11-month-
old children who showed similar 19A carriage levels as compared
to 2009. This is in line with a randomized controlled trial that
compared 19A carriage in PCV10 versus PCV7-vaccinated children
[31] and with data from a post-PCV10 surveillance study on car-
riage by Hammitt et al. which both found no effect of PCV10 on
19A carriage [32]. A possible explanation for the stabilization or
even decline in 19A carriage may be a new balance in competition
between the replacing non-PCV7 serotypes several years following
implementation of PCV7 with no single serotype clearly domi-
nating in carriage, as reported by Hanage and colleagues six to
eight years after PCV7 introduction in Massachusetts [21]. Since
the extra PCV10 serotypes 1, 5, and 7F were rare (≤2%) in our
studies, we speculate that introduction of PCV10 may have had
limited effect on further serotype replacement in carriage between
2010/2011 and 2012/2013. However, follow-up studies need to
conﬁrm whether our data reﬂect a temporal serotype ﬂuctuation,
transitory state, or indeed a newly established balance between
serotypes.
Following implementation of PCV7, the overall IPD cases caused
by serotypes 1, 5, and 7F had slightly increased as observed in the
Netherlands and Germany [19,28]. Three years after the switch
from PCV7 to PCV10, which covers the serotypes 1, 5, and 7F,
the number of IPD cases caused by these serotypes signiﬁcantly
decreased by 42–47% in (unvaccinated) adults aged 18–64 years
old, which likely represents herd effects of infant immunization. A
similar trend was observed in PCV10-vaccinated infants under the
age of two, though not signiﬁcant possibly due to the low number
of cases [28].Whilst serotype 6Adeclined over time following PCV7
implementation, carriage of serotype 6C gradually increased from
2% to 6–7% in infants, thereby becoming the secondmost dominant
serotype in carriage in 2012/2013. Also an increased involvement
of serotype 6C in AOM was seen in the years after PCV7 imple-
mentation [33]. Although 6C is not included in the PCV13 vaccine,
6A in PCV13 possibly elicits cross-protection against serotype 6C
by induction of functional opsonophagocytic responses against 6C
[34].
After PCV7 introduction in the NIP, we also observed an
increased carriage of other potential pathogenic bacteria, espe-
cially S. aureus [17,27], which next to non-vaccine pneumococcal
serotypes, may have contributed to the rise in some respiratory
diseases like empyema [35]. Previously, we reported on increased
S. aureus prevalence in healthy children after PCV7 vaccinations
in a randomized controlled setting [36] and increased involve-
ment of S. aureus after pneumococcal conjugate vaccination in
acute otitis media (AOM) in children with a history of recurrent
otitis who participated in a randomized controlled trial [37]. Our
current data show a return in carriage prevalence of S. aureus
toward (almost) pre-PCV levels in 11-month-old children. Since
interactions between S. aureus and pneumococcal serotypes have
been described in literature [5,38,39], this decline may also be in
line with a new balance in the pneumococcal serotypes and other
colonizers of the nasopharyngeal tract and warrants further inves-
tigation.
Vaccination with PCV7 resulted in increased levels of H.
inﬂuenzae in previous randomized controlled trials after PCV7
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[8] Weinberger DM, Trzcin´ski K, Lu YJ, Bogaert D, Brandes A, Galagan J, et al. Pneu-
mococcal capsular polysaccharide structure predicts serotype prevalence. PLoS
Pathog 2009;5:e1000476, http://dx.doi.org/10.1371/journal.ppat.1000476.A.A.T.M. Bosch et al. /
accinations [40,41] and follow-up surveillance studies [16,17,42].
his coincided with increased involvement of (mainly non-
ypeable) H. inﬂuenzae in otitis media in a RCT on PCV7 and AOM
43] and after the widespread implementation of PCV7 [44,45].
ere we show that carriage of H. inﬂuenzae remained on a high
evel albeit stable on the long term compared with pre-PCV7 vac-
ination data. This was also observed in PCV10 vaccinated children
ven though in PCV10 eight of the ten serotypes are conjugated to
rotein D, a conserved outer membrane protein of non-typeable H.
nﬂuenzae. No effect on H. inﬂuenzae carriage, acquisition, and/or
ensity was previously observed in randomized controlled trials
omparing PCV10 to PCV7 [46] or meningococcal vaccine [47]. In
ontrast, a study performed in Kenya found a reduction in car-
iage of H. inﬂuenzae in the total population after introduction
f PCV10 [32]. The authors, however, question the role of PCV10
s a causative agents since there was an overall reduction in H.
nﬂuenzae carriage and no association between vaccination sta-
us and carriage of H. inﬂuenzae [32]. No consistent changes in
arriage of M. catarrhalis overtime were found [45], also not on
icrobiota level both in PCV7 [41] and PCV10-vaccinated children
48].
Strengths of our study are the consistency of data collec-
ion in repeated large, identically designed, well-deﬁned studies
onducted overtime by the same study group in an open pop-
lation of children and their parents. Moreover, vaccination
overageamongDutch infantsof targetedage-groups ishigh (>95%)
49].
When interpreting our data, some potential limitations should
e considered. Due to the design of the study, causality between
mplementation of PCV7/PCV10 and changes in carriage of well-
nown nasopharyngeal colonizers cannot clearly be established.
he lower overall pneumococcal carriage in 2012/2013 in parents,
ut not in children, compared to previous years is remarkable and
oincided with an increase in number of IPD cases caused by non-
CV10 serotypes in unvaccinated Dutch adults, most signiﬁcantly
n the elderly, in the same period [28]. However, children with
igh density colonization rates rather than parents with relatively
ow carriage prevalence are the key transmitters of non-vaccine
neumococci causing IPD in other age groups. The contribution of
arriage monitoring by culture in healthy, younger adults appears
herefore to be limited. Since there were no changes in the study
rotocols, research team,and laboratoryhandling, theoverall lower
arriage in parents compared to previous years may be explained
y other potential confounders, including viral presence or annual
ariation. Another limitation of our study could be the use of con-
entional culture techniques allowing us to investigate only the
ominating serotypes carried [50]. We may have missed possible
dditional (secondary) serotypes that might have been detected
sing more sensitive diagnostic methods [51,52]. Future surveil-
ance studies on pneumococcal and serotype carriage using both
onventional culture and molecular methods [51,53,54] and inves-
igating not only children but also the elderly are warranted for
better overview of circulating serotypes in the most vulnerable
roups at risk for IPD.
In conclusion, 7 years following implementation of PCV7, 19A
emained the predominant pneumococcal serotype in carriage but
he previous expansion was stopped and 19A carriage even had
eclined in PCV7-vaccinated children. Carriage of H. inﬂuenzae
emained at a higher level, while the S. aureus carriage returned
o pre-PCV7 levels in 11-month-old children. This might indicate
return of a balance between pneumococci and other potential
athogenic bacteria in nasopharyngeal carriage after signiﬁcant
hifts following PCV implementation in the Netherlands. Future
arriage and disease surveillance studies are warranted to monitor
he long-term impact, also of the broader coverage pneumococcal
onjugate vaccines.e 34 (2016) 531–539 537
Funding
This work was supported by the Dutch Ministry of Health, the
Netherlands.
Author contributions
Conceived and designed the experiments: MAH, AJWM, NYR,
EAMS. Performed the study: AATMB, MAH, JPB. Analyzed the data:
AATMB, EAMS. Contributed reagents/materials/analysis tools: KT,
DB, JPB. Drafted of the manuscript: AATMB, MAH, AJWM, NYR, JPB,
DB, KT, EAMS.
Conﬂict of interest statement
EAMS declares to have received unrestricted research support
from Pﬁzer, grant support for vaccine studies from Pﬁzer and GSK
and fees paid to the institution for advisory boards or participation
in independent data monitoring committees for Pﬁzer and GSK.
None of the fees or grants listed here was received for the research
described in this paper. All other authors report no potential con-
ﬂicts.
Acknowledgments
This work is dedicated to the memory of Dr. R. H. Veenhoven
who contributed to the planning of the design and execution of the
study. We wish to thank all the members of the research team, the
laboratory staff and the cooperating institutes for their dedication
to the projects. Especially we thank P. Badoux and L. Kosten for
their laboratory support, M. Knol for her support with statistical
analysis, and E. van Gils for helpful discussion. Most of all, we are
indebted to all the participating children and their families.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.vaccine.2015.11.
060.
References
[1] Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O’Brien LK. The funda-
mental link between pneumococcal carriage and disease. Expert Rev Vaccines
2012;11:841–55, http://dx.doi.org/10.1586/erv.12.53.
[2] Weinberger DM, Harboe ZB, Sanders EAM, Ndiritu M, Klugman KP,
Rückinger S, et al. Association of serotype with risk of death due to
pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010;51:692–9,
http://dx.doi.org/10.1086/655828.
[3] Weinberger DM, Bruden DT, Grant LR, Lipsitch M, O’Brien KL, Pelton
SI, et al. Using pneumococcal carriage data to monitor postvaccina-
tion changes in invasive disease. Am J Epidemiol 2013;178:1488–95,
http://dx.doi.org/10.1093/aje/kwt156.
[4] Weinberger DM, Harboe ZB, Flasche S, Scott JA, Lipsitch M. Prediction
of serotypes causing invasive pneumococcal disease in unvacci-
nated and vaccinated populations. Epidemiology 2011;22:199–207,
http://dx.doi.org/10.1097/EDE.0b013e3182087634.
[5] Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral, Bacte-
rial interactions in the upper respiratory tract. PLoS Pathog 2013;9:e1003057,
http://dx.doi.org/10.1371/journal.ppat.1003057.
[6] Leiberman A, Dagan R, Leibovitz E, Yagupsky P, Fliss DM. The bacteriology of
the nasopharynx in childhood. Int J Pediatr Otorhinolaryngol 1999;49(Suppl
1):S151–3.
[7] Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisa-
tion: the key to pneumococcal disease. Lancet Infect Dis 2004;4:144–54,
http://dx.doi.org/10.1016/S1473-3099(04)00938-7.[9] Sleeman KL, Grifﬁths D, Shackley F, Diggle L, Gupta S, Maiden MC, et al.
Capsular serotype–speciﬁc attack rates and duration of carriage of
5 Vaccin
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[38 A.A.T.M. Bosch et al. /
Streptococcus pneumoniae in a population of children. J Infect Dis
2006;194:682–8, http://dx.doi.org/10.1086/505710.
10] Harboe ZB, Benﬁeld TL, Valentiner-Branth P, Hjuler T, Lambertsen L,
Kaltoft M, et al. Temporal trends in invasive pneumococcal disease and
pneumococcal serotypes over 7 decades. Clin Infect Dis 2010;50:329–37,
http://dx.doi.org/10.1086/649958.
11] Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance
L, Reithinger R, et al. Systematic evaluation of serotypes causing inva-
sive pneumococcal disease among children under ﬁve: the pneumococ-
cal global serotype project. PLoS Med 2010;7:e1000348, http://dx.doi.
org/10.1371/journal.pmed.1000348.
12] Van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP,
et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate
vaccine on nasopharyngeal pneumococcal carriage in children: a randomized
controlled trial. JAMA 2009;302:159–67.
13] Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, et al.
Effects of pneumococcal conjugate vaccine 2 years after its introduction, the
Netherlands. Emerg Infect Dis 2010;16:816–23.
14] Van Deursen AM, van Mens SP, Sanders EAM, Vlaminckx BJ, de Melker HE,
Schouls LM, et al. Invasive pneumococcal disease and 7-valent pneumococcal
conjugate vaccine, the Netherlands. Emerg Infect Dis 2012;18:1729–37.
15] Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynﬁeld R,
et al. Decline in invasive pneumococcal disease after the introduction of
protein–polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737–46,
http://dx.doi.org/10.1056/NEJMoa022823.
16] Spijkerman J, van Gils EJM, Veenhoven RH, Hak E, Yzerman EP, van den Ende
A, et al. Carriage of Streptococcus pneumoniae 3 years after start of vaccination
program, the Netherlands. Emerg Infect Dis 2011;17:584–91.
17] Spijkerman J, Prevaes SMPJ, van Gils EJM, Veenhoven RH, Bruin JP, Bogaert D,
et al. Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal
carriage of S. pneumoniae, S., aureus, H. inﬂuenzae and M. catarrhalis. PLoS ONE
2012;7:e39730, http://dx.doi.org/10.1371/journal.pone.0039730.
18] Scott JR, Millar EV, Lipsitch M, Moulton LH, Weatherholtz R, Perilla MJ, et al.
Impact of more than a decade of pneumococcal conjugate vaccine use on
carriage and invasive potential in Native American communities. J Infect Dis
2012;15:280–8.
19] Van der Linden M, Falkenhorst G, Perniciaro S, Imöhl M. Effects of infant
pneumococcal conjugate vaccination on serotype distribution in invasive
pneumococcal disease among children and adults in Germany. PLoS ONE
2015;10:e0131494, http://dx.doi.org/10.1371/journal.pone.0131494.
20] Ansaldi F, de Florentiis D, Canepa P, Zancolli M, Martini M, Orsi A, et al. Carriage
of Streptoccoccus pneumoniae 7 years after implementation of vaccination pro-
gram in a population with very high and long-lasting coverage, Italy. Vaccine
2012;30:2288–94, http://dx.doi.org/10.1016/j.vaccine.2012.01.067.
21] Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE, Kleinman K,
et al. Evidence that pneumococcal serotype replacement in Massachusetts
following conjugate vaccination is now complete. Epidemics 2010;2:80–4,
http://dx.doi.org/10.1016/j.epidem.2010.03.005.
22] Weil-Olivier C, van der L, de Schutter I, Dagan R, Mantovani L. Prevention
of pneumococcal diseases in the post-seven valent vaccine era: a European
perspective. BMC Infect Dis 2012;12:207.
23] Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV.
Pneumococcal serotypes before and after introduction of conju-
gate vaccines, United States, 1999–2011. Emerg Infect Dis 2013:19,
doi:http://dx.doi.org/10.3201/eid1907.121830.
24] van der Linden Reinert RR, Kern W, Imohl M. Epidemiology of serotype 19A
isolates from invasive pneumococcal disease in German children. BMC Infect
Dis 2013;13:70.
25] O’Brien KL, Nohynek H, World Health Organization Pneumococcal Vaccine Tri-
als Carriage Working Group. Report from a WHO Working Group: standard
method for detecti. . . Report from a WHO Working Group: standard method
for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr
Infect Dis J 2003;22:e1–11.
26] Watt JP, O’Brien KL, Katz S, Bronsdon MA, Elliot J, Dallas J, et al.
Nasopharyngeal versus oropharyngeal sampling for detection of
pneumococcal carriage in adults. J Clin Microbiol 2004;42:4974–6,
http://dx.doi.org/10.1128/JCM.42.11. 4974-4976.2004.
27] Van Gils E, Hak E, Veenhoven R, Rodenburg G, Bogaert D, Bruin J, et al. Effect of
seven-valentpneumococcal conjugatevaccineon Staphylococcus aureus coloni-
sation in a randomised controlled trial. PLoS ONE 2011;6:e20229.
28] Knol M, Wagenvoort G, Sanders E, Elberse K, Vlaminckx B, de Melker H,
et al. Invasive pneumococcal disease 3 years after introduction of 10-valent
pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis 2015,
doi:http://dx.doi.org/10.3201/eid2111.140780 (epub ahead).
29] Jokinen J, Rinta-Kokko H, Siira L, Palmu AA, Virtanen MJ, Nohynek H, et al.
Impact of ten-valent pneumococcal conjugate vaccination on invasive pneu-
mococcal disease in Finnish children—a population-based study. PLoS ONE
2015;10:e0120290, http://dx.doi.org/10.1371/journal.pone.0120290.
30] Domingues CMAS, Verani JR, Montenegro Renoiner EI, de Cunto Brandileone
MC, Flannery B, de Oliveira LH, et al. Effectiveness of ten-valent pneu-
mococcal conjugate vaccine against invasive pneumococcal disease in
Brazil: a matched case-control study. Lancet Respir Med 2014;2:464–71,
http://dx.doi.org/10.1016/S2213-2600(14)70060-8.
[e 34 (2016) 531–539
31] Van den Bergh MR, Spijkerman J, Swinnen KM, Franc¸ois NA, Pascal TG, Borys D,
et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus inﬂuen-
zae protein d-conjugate vaccine on nasopharyngeal bacterial colonization in
young children: a randomized controlled trial. Clin Infect Dis 2013;56:e30–9,
http://dx.doi.org/10.1093/cid/cis922.
32] Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, et al. Pop-
ulation effect of 10-valent pneumococcal conjugate vaccine onnasopharyngeal
carriage of Streptococcus pneumoniae and non-typeable Haemophilus inﬂuen-
zae in Kiliﬁ, Kenya: ﬁndings from cross-sectional carriage studies. Lancet Glob
Heal 2014;2:e397–405, http://dx.doi.org/10.1016/S2214-109X(14)70224-4.
33] Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent
pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage
in children with acute otitis media. Pediatr Infect Dis J 2012;31:297–301,
http://dx.doi.org/10.1097/INF.0b013e318247ef84.
34] Cooper D, YuX, SidhuM,NahmMH, Fernsten P, Jansen KU. The 13-valent pneu-
mococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic
killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.
Vaccine 2011;29:7207–11, http://dx.doi.org/10.1016/j.vaccine.2011.06.056.
35] Burgos J, Falcó V, Pahissa A. The increasing incidence of empyema.
Curr Opin Pulm Med 2013;19:350–6, http://dx.doi.org/10.1097/
MCP.0b013e3283606ab5.
36] Van Gils E, Veenhoven R, Hak E, Rodenburg G, Keijzers W, Bogaert D, et al.
Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneu-
mococcal serotype 19A strains. JAMA 2010;304:1099–106.
37] Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, et al.
Effect of conjugate pneumococcal vaccine followed by polysaccharide pneu-
mococcal vaccine on recurrent acute otitis media: a randomised study. Lancet
2003;361:2189–95, http://dx.doi.org/10.1016/S0140-6736(03)13772-5.
38] Dunne EM, Smith-Vaughan HC, Robins-Browne RM, Mulholland EK, Satzke
C. Nasopharyngeal microbial interactions in the era of pneumococcal con-
jugate vaccination. Vaccine 2013;31:2333–42, http://dx.doi.org/10.1016/j.
vaccine.2013.03.024.
39] Regev-Yochay G, Lipsitch M, Basset A, Rubinstein E, Dagan R, Raz M,
et al. The pneumococcal pilus predicts the absence of Staphylococcus
aureus co-colonization in pneumococcal carriers. Clin Infect Dis 2009;48:
760–3.
40] Van Gils EJM, Veenhoven RH, Rodenburg GD, Hak E, Sanders EAM.
Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal
carriage with Haemophilus inﬂuenzae and Moraxella catarrhalis in a random-
ized controlled trial. Vaccine 2011;29:7595–8, doi:http://dx.doi.org/10.1016/
j.vaccine.2011.08.049.
41] Biesbroek G, Wang X, Keijser BJF, Eijkemans RMJ, Trzcin´ski K, Rots
NY, et al. Seven-valent pneumococcal conjugate vaccine and nasopharyn-
geal microbiota in healthy children. Emerg Infect Dis 2014;20:201–10,
http://dx.doi.org/10.3201/eid2002.131220.
42] Camilli R, Vescio MF, Giufrè M, Daprai L, Garlaschi ML, Cerquetti M,
et al. Carriage of Haemophilus inﬂuenzae is associated with pneu-
mococcal vaccination in Italian children. Vaccine 2015;33:4559–64,
http://dx.doi.org/10.1016/j.vaccine.2015.07.009.
43] Eskola J, Kilpi T, Palmu A, Jokinen J, Eerola M, Haapakoski J, et al. Efﬁcacy of
a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med
2001;344:403–9, http://dx.doi.org/10.1056/NEJM200102083440602.
44] Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens
causing acute otitis media six to eight years after introduction of
pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010;29:304–9,
http://dx.doi.org/10.1097/INF.0b013e3181c1bc48.
45] Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG,
et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute
otitis media in children: a systematic review. JAMA 2010;304:2161–9,
http://dx.doi.org/10.1001/jama.2010.1651.
46] Bergh MR, Spijkerman J, Swinnen KM, Francois NA, Pascal TG, Borys D,
et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus inﬂuen-
zae protein D–conjugate vaccine on nasopharyngeal bacterial colonization in
young children: a randomized controlled trial. Clin Infect Dis 2013;56:e30–9,
http://dx.doi.org/10.1093/cid/cis922.
47] Prymula R, Hanovcova I, Splino M, Kriz P, Motlova J, Lebedova V, et al. Impact
of the 10-valent pneumococcal non-typeable Haemophilus inﬂuenzae protein
D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine
2011;29:1959–67, http://dx.doi.org/10.1016/j.vaccine.2010.12.086.
48] Feazel LM, Santorico SA, Robertson CE, Bashraheil M, Scott JAG, Frank DN,
et al. Effects of vaccination with 10-valent pneumococcal non-typeable
Haemophilus inﬂuenza protein D conjugate vaccine (PHiD-CV) on the nasopha-
ryngeal microbiome of Kenyan toddlers. PLoS ONE 2015;10:e0128064,
http://dx.doi.org/10.1371/journal.pone.0128064.
49] Van Lier EA, Oomen PJ, Oostenbrug MWM, Zwakhals SLN, Drijfhout IH,
de Hoogh PAAM, et al. High vaccination coverage of the National Immu-
nization Programme in the Netherlands. Ned Tijdschr Geneeskd 2009;153:
950–7.50] Huebner RE, Dagan R, Porath N, Wasas AD, Klugman TMKP. Lack of utility
of serotyping multiple colonies for detection of simultaneous nasopha-
ryngeal carriage of different pneumococcal serotypes. Pediatr Infect Dis J
2000;19:1017–20.
Vaccin
[
[
[
Streptococcus pneumoniae colonization in adults. PLoS ONE 2013;8:e60520,A.A.T.M. Bosch et al. /
51] Wyllie AL, Chu MLJN, Schellens MHB, van Engelsdorp Gastelaars
J, Jansen MD, van der Ende A, et al. Streptococcus pneumoniae in
saliva of Dutch primary school children. PLoS ONE 2014;9:e102045,
http://dx.doi.org/10.1371/journal.pone.0102045.
52] TurnerP,Hinds J, TurnerC, JankhotA,GouldK,BentleySD, et al. Improveddetec-
tion of nasopharyngeal cocolonization by multiple pneumococcal serotypes
by use of latex agglutination or molecular serotyping by microarray. J Clin
Microbiol 2011;49:1784–9, http://dx.doi.org/10.1128/JCM. 00157-11.
[e 34 (2016) 531–539 539
53] Trzcin´ski K, Bogaert D, Wyllie A, Chu MLJN, van der Ende A, Bruin JP,
et al. Superiority of trans-oral over trans-nasal sampling in detectinghttp://dx.doi.org/10.1371/journal.pone.0060520.
54] Krone CL, Wyllie AL, van Beek J, Rots NY, Oja AE, Chu MLJN, et al. Carriage of
Streptococcus pneumoniae in aged adults with inﬂuenza-like-illness. PLoS ONE
2015;10:e0119875, http://dx.doi.org/10.1371/journal.pone.0119875.
